NVNO (enVVeno Medical Corporation Common Stock) Stock Analysis - News
enVVeno Medical Corporation Common Stock (NVNO) is a publicly traded Healthcare sector company. As of May 21, 2026, NVNO trades at $10.95 with a market cap of $6.56M and a P/E ratio of -0.30. NVNO moved -1.77% today. Year to date, NVNO is -10.61%; over the trailing twelve months it is -91.38%. Its 52-week range spans $8.67 to $196.70. Rallies surfaces NVNO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in NVNO news today?
enVVeno Medical CEO Details FDA IDE Approval for Venous Valve Pivotal Study: enVVeno Medical secured the first-ever FDA IDE approval for a U.S. pivotal study of its non-surgical enVVe venous valve targeting roughly 3 million deep venous insufficiency patients. CEO Robert Berman outlined development milestones and study advancement in a newly released Virtual Investor segment.
Duhay Francis sold 4.90K (~$1.74K) on Dec 11, 2025.
Duhay Francis sold 4.90K (~$4.07K) on Sep 15, 2025.
NVNO Analyst Consensus
NVNO analyst coverage data. Average price target: $0.00.
Common questions about NVNO
What changed in NVNO news today?
enVVeno Medical CEO Details FDA IDE Approval for Venous Valve Pivotal Study: enVVeno Medical secured the first-ever FDA IDE approval for a U.S. pivotal study of its non-surgical enVVe venous valve targeting roughly 3 million deep venous insufficiency patients. CEO Robert Berman outlined development milestones and study advancement in a newly released Virtual Investor segment.
Does Rallies summarize NVNO news?
Yes. Rallies summarizes NVNO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is NVNO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NVNO. It does not provide personalized investment advice.
